VirTrial

JULY 1, 2024

Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Clinical Supply 59

VirTrial

JULY 1, 2024

Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Supply 52

VirTrial

JULY 1, 2024

Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Supply 52

VirTrial

JULY 1, 2024

Don’t involve RTSM too late If it’s beneficial to involve RTSM early , then conversely, it’s a bad thing to leave RTSM development until closer to FPI. Delaying RTSM development increases the risk of compromises, phased deliveries, or worst-case scenario, needing enhancements mid-study. That’s common sense.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Clinical Supply 40